Schindler, L.; Moosbauer, J.; Schmidt, D.; Spruss, T.; Grätz, L.; Lüdeke, S.; Hofheinz, F.; Meister, S.; Echtenacher, B.; Bernhardt, G.;
et al. Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors. Cancers 2022, 14, 4922.
https://doi.org/10.3390/cancers14194922
AMA Style
Schindler L, Moosbauer J, Schmidt D, Spruss T, Grätz L, Lüdeke S, Hofheinz F, Meister S, Echtenacher B, Bernhardt G,
et al. Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors. Cancers. 2022; 14(19):4922.
https://doi.org/10.3390/cancers14194922
Chicago/Turabian Style
Schindler, Lisa, Jutta Moosbauer, Daniel Schmidt, Thilo Spruss, Lukas Grätz, Steffen Lüdeke, Frank Hofheinz, Sebastian Meister, Bernd Echtenacher, Günther Bernhardt,
and et al. 2022. "Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors" Cancers 14, no. 19: 4922.
https://doi.org/10.3390/cancers14194922
APA Style
Schindler, L., Moosbauer, J., Schmidt, D., Spruss, T., Grätz, L., Lüdeke, S., Hofheinz, F., Meister, S., Echtenacher, B., Bernhardt, G., Pietzsch, J., Hellwig, D., & Keller, M.
(2022). Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors. Cancers, 14(19), 4922.
https://doi.org/10.3390/cancers14194922